Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD123/TOP1i antibody-drug conjugate AZD9829

An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against the interleukin-3 (IL3)-receptor alpha chain (CD123; IL-3RA) conjugated to a topoisomerase-1 inhibitor (TOP1i), with potential antineoplastic activity. Upon administration of anti-CD123/TOP1i ADC AZD9829, the antibody moiety targets and binds to the cell surface antigen CD123 expressed on tumor cells. Upon binding and internalization, the TOP1i moiety is released, binds to TOP1 and stabilizes cleaved DNA-TOP1 complexes. This prevents DNA re-ligation, induces irreversible DNA strand breaks, prevents DNA repair, and leads to cycle arrest and apoptosis specifically in tumor cells expressing CD123. CD123 regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers, including myeloid leukemia, and increased expression of CD123 on leukemic stem cells is associated with poor prognosis.
Synonym:anti-CD123 ADC AZD9829
anti-CD123 antibody-drug conjugate AZD9829
anti-CD123/TOP1i ADC AZD9829
Code name:AZD 9829
AZD-9829
AZD9829
Search NCI's Drug Dictionary